<DOC>
	<DOCNO>NCT02963311</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , efficacy ALN-PCSSC participant homozygous familial hypercholesterolemia .</brief_summary>
	<brief_title>A Study ALN-PCSSC Participants With Homozygous Familial Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Males female , â‰¥12 year age diagnosis homozygous familial hypercholesterolemia genetic confirmation clinical diagnosis base history untreated lowdensity lipoprotein cholesterol ( LDLC ) concentration &gt; 500 milligrams/deciliter ( mg/dL ) [ 13 millimoles/liter ( mmol/L ) ] together either xanthoma 10 year age evidence heterozygous familial hypercholesterolemia parent . Stable lowfat diet . Stable preexisting , lipidlowering therapy ( statin , cholesterolabsorption inhibitor , bileacid sequestrants , combination thereof ) least 4 week plan medication dose change duration study participation . Fasting central lab LDLC concentration &gt; 130 mg/dL ( 3.4 mmol/L ) triglyceride concentration &lt; 400 mg/dL ( 4.5 mmol/L ) . Body weight 40 kilogram ( kg ) great screen . Should willing able give write informed consent initiation studyrelated procedure ( participant less 18 year age , write consent obtain guardian legally authorize representative , verbal assent child ) . Should willing comply require study procedure . LDL plasma apheresis within 8 week prior screen visit , plan receive study attendant difficulty maintain stable concentration LDLC receive apheresis . Use mipomersen lomitapide therapy within 5 month screen . Previous treatment monoclonal antibody direct towards PCSK9 within 8 week screen . New York Heart Association ( NYHA ) class III IV heart failure last known leave ventricular ejection fraction &lt; 30 % cardiac arrhythmia within past 3 month control medication . Myocardial infarction , unstable angina , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) stroke within 3 month enrollment . Planned cardiac surgery revascularization . Uncontrolled severe hypertension , define systolic blood pressure &gt; 180 millimeter mercury ( mmHg ) diastolic blood pressure &gt; 110 mmHg prior enrollment despite antihypertensive therapy . Poorly control diabetes mellitus , , glycated hemoglobin A1c ( HbA1c ) &gt; 10.0 % prior enrollment . Estimated glomerular filtration rate ( eGFR ) &lt; 30 ml/minute/1.73 meters^2 . Active liver disease define know current infectious , neoplastic , metabolic pathology liver unexplained alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , elevation &gt; 3 time upper limit normal ( ULN ) , screen confirm repeat measurement least 1 week apart . Creatine kinase ( CK ) &gt; 5 time ULN without know cause . Other serious comorbid disease life expectancy participant short duration trial ( example , acute systemic infection , serious illness ) . Any history malignant disease , exception treat basalcell carcinoma occur &gt; 5 year screen . Females pregnant nursing , childbearing potential ( include adolescent female reach menarche sexually active ) unwilling use least two method contraception ( example , oral contraceptive , barrier method , approve contraceptive implant , long term injectable contraception , intrauterine device ) entire duration study . Exemptions criterion follow : 1 . Women &gt; 2 year postmenopausal ( define 1 year longer since last menstrual period ) 55 year age 2 . Postmenopausal woman ( define ) less 55 year old negative pregnancy test within 24 hour enrollment 3 . Women surgically sterilize least 3 month prior enrollment 4 . Adolescent female reach menarche Males unwilling use acceptable method birth control ( example , condom spermicide ) entire study period . Known history alcohol and/or drug abuse within 5 year . Any condition accord investigator could interfere conduct study , limit following : 1 . Inappropriate study , include participant unable communicate cooperate investigator . 2 . Unable understand protocol requirement , instruction , studyrelated restriction nature , scope , possible consequence study ( include participant whose cooperation doubtful due drug abuse alcohol dependency ) . 3 . Unlikely comply protocol requirement , instruction , studyrelated restriction ( example , uncooperative attitude , inability return followup visit , improbability complete study ) . 4 . Have medical surgical condition opinion investigator would put participant increase risk participate study . 5 . Involved , relative , someone directly involve conduct study . Any clinically significant disease condition affect major organ system , include limited gastrointestinal , renal , hepatic , endocrinologic , pulmonary , neurological , metabolic , cardiovascular disease . Any surgical medical condition judgment Investigator , might interfere pharmacokinetics , distribution , metabolism , excretion study drug ( applicable ) . Treatment investigational medicinal product device within 30 day 5 halflives , whichever longer , prior administration study drug/device plan use investigational medicinal product device . Previous participation study precede study ALNPCSSC . Hypersensitivity ingredient study drug use .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>